Pathology: es-BC - TNBC - NA - all population; es-BC - TNBC - NA - PDL1 positive; mBC - TNBC - L1 - all population; mBC - TNBC - L1 - PDL1 positive;
| es-BC - TNBC - NA - all population | es-BC - TNBC - NA - PDL1 positive | mBC - TNBC - L1 - all population | mBC - TNBC - L1 - PDL1 positive | |||||
| NeoTRIPaPDLA, 0 | IMpassion-031 (all population), 2020 | IMpassion-031 (PDL1>1%), 2020 | IMpassion-130 (all population), 2018 | IMpassion-131 (all population), 2020 | IMpassion-130 (PDL1>1%), 2018 | IMpassion-131 (PD-L1 > 1%), 2020 | ||
| atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide | 2 | T1 | T1 | |||||
| atezolizumab plus paclitaxel | 2 | T1 | T1 | |||||
| atezolizumab plus nab-paclitaxel | 2 | T1 | T1 | |||||
| atezolizumab plus carboplatin plus nab-paclitaxel | 1 | T1 | ||||||
| carboplatin plus nab-paclitaxel | 0 | T0 | ||||||
| placebo plus SoC | 0 | T0 | T0 | |||||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | |||